By Dan Levine and Mike Spector

(Reuters) – Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck (NSE:) if he is confirmed as President Donald Trump’s secretary of the U.S. Department of Health and Human Services, according to a federal ethics disclosure made public on Wednesday.

Kennedy, who ended his own presidential campaign last year to endorse Trump, is set for a U.S. Senate hearing on his nomination next week. As HHS secretary, Kennedy would wield enormous influence over the pharma industry, and the nomination is opposed by several health and consumer organizations over Kennedy’s role in sowing doubt about the safety and efficacy of vaccines.

Reuters reported last week that Kennedy played an instrumental role in organizing mass litigation against Merck over its human papillomavirus shot Gardasil. One of the main lawyers suing Merck, Michael Baum, told Reuters that Kennedy “taught us” how to pursue Gardasil claims outside a special government-run vaccine compensation program that limits pharma company liability.

Kennedy has an arrangement to earn 10 percent of fees awarded in contingency cases he refers to Baum’s firm WisnerBaum, according to a letter Kennedy wrote to an HHS ethics official released on Wednesday. If confirmed, Kennedy would retain that financial interest in cases that do not directly impact the U.S. government, the letter said.

Kennedy and Baum did not immediately respond to requests for comment. Merck declined to comment.

High-level U.S. government officials routinely disclose financial interests and potential conflicts during the nomination process.

Kennedy wrote that he is “not an attorney of record” for his WisnerBaum cases. However, Kennedy filed official court appearances in several Gardasil cases, including one set for trial in Los Angeles this week, court dockets show. As of Wednesday, Kennedy had not appeared to have withdrawn from them.

© Reuters. Donald Trump's nominee to be U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., in the Statuary Hall of the U.S. Capitol before the luncheon on the inauguration day of U.S. President Donald Trump's second Presidential term in Washington, U.S., January 20, 2025. REUTERS/Evelyn Hockstein

In a separate ethics disclosure, Kennedy reported at least $857,000 from WisnerBaum, and did not specify which cases generated that income. Kennedy has collaborated with WisnerBaum on litigation over Monsanto (NYSE:)’s weed killer Roundup.

The Gardasil lawsuits allege Merck had fraudulently advertised the vaccine as safe, overstating its benefits while concealing knowledge of dangerous side effects. Merck says the cases have no merit and that research supports the safety of its HPV vaccines.


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.